Lambert-eaton Myasthenic Syndrome
10
2
2
4
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 37/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
50%
2 of 4 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 4 completed trials
Clinical Trials (10)
Effects of Whole-body Electrical Muscle Stimulation Exercise on Adults With Neuromuscular Disease
Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
Patient Observation With Environmental and Wearable Sensors in Myasthenia Gravis
Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)
Treatment of Lambert-Eaton Syndrome With 3,4 Diaminopyridine
Phase 3 Study to Evaluate Efficacy of Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS)
Effectiveness of 3,4-Diaminopyridine in Lambert-Eaton Myasthenic Syndrome
Use Of 3,4-Diaminopyridine (3,4-DAP) In The Treatment Of Lambert Eaton Myasthenic Syndrome
Randomized Study of 3,4-Diaminopyridine for Lambert-Eaton Myasthenic Syndrome